Alligator Bioscience to sell mitazalimab rights to Biossil for $0.75M upfront
Alligator Bioscience agreed to transfer all mitazalimab rights to Biossil for $0.75M upfront and up to $108M in milestones. Closing is expected within 30 days.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Alligator Bioscience (ATORX) has agreed to sell all of its rights to mitazalimab to Biossil. Under the terms, Alligator will receive $0.75 million upfront and up to $108 million in milestone payments, tied to approvals and sales of the drug.
The deal also includes royalties in the mid-single-digit range, with total payments capped at $250 million. Closing is expected within 30 days and is subject to conditions, according to TradingView, which cites the company's press release.
why it matters
According to the analysis TradingView cites, the sale helps Alligator cut costs and focus on its economic interest in HLX22. For the broader market the news is modest: the upfront payment is small, and most of the potential value depends on future regulatory progress by Biossil.
tags
instruments
sources
- Alligator Bioscience (ATORX) Sells Mitazalimab For $0.75M Upfront, Up To $108M Milestones — TradingView, 31 October 2026 at 07:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗